Abstract
AbstractmRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, we have witnessed the development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based mRNA vaccines. The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases. Finally, we will discuss the challenge of mRNA vaccines against bacterial and parasitic diseases.
Funder
the National Natural Science Foundation Regional Innovation and Development
National Major Scientific and Technological Special Project for “Significant New Drugs Development”
the Excellent Youth Foundation of Sichuan Scientific Committee Grant in China
the Development Program of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Reference225 articles.
1. Rabinovich NR, McInnes P, Klein DL, Hall BF. Vaccine technologies: view to the future. Science. 1994;265:1401–4.
2. Moore ZS, Seward JF, Lane JM. Smallpox. Lancet. 2006;367:425–35.
3. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9.
4. Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol. 2015;16:e56.
5. Rodrigues CMC, Pinto MV, Sadarangani M, Plotkin SA. Whither vaccines? J Inf Secur. 2017;74(Suppl 1):S2–s9.
Cited by
185 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献